Objective To investigate the clinical effect and safety of albumin-bound paclitaxel( Nab-P) as the first-line treatment for advanced primary liver cancer. Methods A retrospective analysis was performed for the clinical data of 23 patients with advanced primary liver cancer who were admitted to the Department of Medical Oncology in Chinese PLA General Hospital from May 2014 to December 2015.According to the treatment regimen,these patients were divided into observation group and control group. The 12 patients in the observation group were treated with Nab-P,among whom 5 were treated with Nab-P combined with tegafur,gimeracil and oteracil,5 were treated with Nab-P combined with capecitabine,and 2 were treated with Nab-P alone; the 11 patients in the control group were treated with gemcitabine combined with oxaliplatin. One cycle of the treatment was 21 days for each treatment regimen; therapeutic effect was evaluated every2 cycles,and adverse events were evaluated every cycle. The chi-square test or the Fisher's exact test was used for comparison of categorical data between groups,the Kaplan-Meier survival curves were used to analyze progression-free survival,and the log-rank test was used to compare survival rates between groups. Results All the patients were eligible for evaluation of clinical outcome and adverse events.In the observation group,2 patients achieved partial remission,7 had a stable disease,and 3 had a progressive disease; in the control group,2 achieved partial remission,5 had a stable disease,and 4 had a progressive disease. There was no significant difference in disease control rate between the two groups( 75% vs 64%,χ2= 0. 350,P > 0. 05). There was also no significant difference in the median progression-free survival between the two groups [5. 1( 2. 7-6. 7) months vs 4. 3( 2. 5-5. 4) months,χ2= 0. 647,P > 0. 05]. As for adverse events,no patient experienced serious adverse events,and there were significant differences in the incidence rates of platelet toxicity and increased aspartate aminotransferase between the two groups( χ2= 5. 490 and 6. 135,P = 0. 036 and 0. 027). Conclusion In the treatment of advanced primary liver cancer,the medication based on Nab-P shows a good clinical effect and tolerable toxic and side effects; however,due to the small sample size in this study,the clinical studies with a large sample size are needed.
[1]CHEN WQ,ZHENG RS,BAADE PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
|
[2]ROH Y,DAVID KC,SONG S,et al.The prognosis and treatment outcomes of patients with recurrent hepatocellular carcinoma after liver transplantation[J].Clin Transplant,2014,28(1):141-148.
|
[3]BRUIX J,SHERMAN M,LLOVET JM,et al.EASL panel of experts on HCC clinical management of hepatocellular carcinoma:conclusions of the Barcelona-2000 EASL conference[J].J Hepatol,2001,35(3):421-430.
|
[4]YE SL,CHEN RX.Comments on management of hepatocellular carcinoma:an update[J].Chin J Hepatol,2011,19(4):251-254.(in Chinese)叶胜龙,陈荣新.《肝细胞癌临床指南更新》解读[J].中华肝脏病杂志,2011,19(4):251-254.
|
[5]GONG S,SUN JM,TIAN LL,et al.Research progress of the anti-tumor effect of alkaloids of natural medicine[J].Jilin J Tradit Chin Med,2014,34(9):927-931.(in Chinese)宫爽,刘佳明,田淋淋,等.天然药物中生物碱类成分抗肿瘤活性[J].吉林中医药,2014,34(9):927-931.
|
[6]XIE LL,YANG TJ,ZHANG CP,et al.Clinical progress on nanoparticle albumin-bound paclitaxel[J].J Pharm Res,2014,33(5):289-291.
|
[7]LI Z,ZHANG WG,HAN XW.Recent advances in interventional therapy of hepatocellular carcinoma[J].World Chin J Dig,2011,19(3):221-226.(in Chinese)李臻,张文广,韩新巍.原发性肝细胞癌介入治疗的现状与进展[J].世界华人消化杂志,2011,19(3):221-226.
|
[8]RAOUL JL,SANGRO B,FOMER A,et al.Evolving strategies for the management of intermediate-stage hepatocellular carcinoma:available evidence and expert opinion on the use of transarterial chemoembo Iization[J].Cancer Treat Rev,2011,37(3):212-220.
|
[9]WANG F,QIN SK,HUA HQ,et al.Report of two cases of hepatitis B virus reactivation in primary liver carcinoma patients treated with the FOLFOX chemotherapy regimen[J].Chin J Hepatol,2014,22(3):236-238.(in Chinese)王锋,秦叔逵,华海清,等.FOLFOX4方案治疗晚期肝癌引起乙型肝炎病毒再激活2例报道[J].中华肝脏病杂志,2014,22(3):236-238.
|
[10]YI WL,FANG L,LIAO XL,et al.A clinical study of gemcitabine plus oxaliplatin in the treatment of advanced primary liver cancer[J].J Guangxi Med Univ,2014,31(5):756-760.(in Chinese)义维丽,房亮,廖小莉,等.吉西他滨联合奥沙利铂治疗中晚期原发性肝癌的临床疗效和安全性观察[J].广西医科大学学报,2014,31(5):756-760.
|
[11]LI HT,LEI YQ,HUANG JH,et al.Study of the efficacy and safety of GEMOX regimen for the patients with advanced primary liver cancer[J].J Clin Exp Med,2014,13(4):274-276.(in Chinese)李海涛,雷叶青,黄劲华,等.吉西他滨联合奥沙利铂治疗晚期原发性肝癌患者的疗效和安全性研究[J].临床和实验医学杂志,2014,13(4):274-276.
|
[12]ZHANG SM,ZHANG N.Research progress of hepatocellular carcinoma chemotherapy[J].Chin J New Drugs Clin Rem,2015,34(2):93-98.
|
[13]SWET JH,PACHECO HJ,IANNITI DA,et al.A silica-calcium-phosphate nanocomposite drug delivery system for the treatmentof hepatocellular carcinoma:in vivo study[J].J Biomed Mater Res,2014,102(1):190-202.
|
[14]WANG L,LI M,ZHANG N.Folate-targeted docetaxel-lipidbased-nanosuspensions for active-targeted cancer therapy[J].Int J Nanomed,2012,7(7):3281-3294.
|
[15]ZHOU Q,SUN X,ZENG L,et al.A randomized multicenter phaseⅡclinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma[J].Nanomedicine,2009,5(4):419-423.
|
[16]JOHN TA,VOGEL SM,TIRUPPATHI C,et al.Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer[J].Am J Physiol Lung Cell Mol Physiol,2003,184(1):184-196.
|
[17]TENERIELLO MG,TSENG PC,CROZIER M,et al.PhaseⅡevaluation of nanopartiele albumin-bound paclitaxel in platinumsensitive patients with recurrent ovarian,peritoneal,or fallopian tube cancer[J].J Clin Oncol,2009,27(9):1426-1431.
|
[18] 医療用医薬品:アブラキサン[EB/OL].http://www.kegg.jp/medicus-bin/japic_med?japic_code=00058810
|
[19]XU J,LIU ZS,ZHANG ZL.Effects of paclitaxel on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice[J].Wuhan Univ J Med Sci,2005,26(4):449-451.(in Chinese)许俊,刘志苏,张中林.紫杉醇对裸鼠人肝癌血管生成和肿瘤生长、转移的作用[J].武汉大学学报:医学版,2005,26(4):449-451.
|
[20]MA YL,QI HY,CAO ZD,et al.Studies on the preparation of docetaxel nano-liposomes and its treatment on liver cancer cells in vivo and in vitro[J].Chin J Biological Pharms,2015,35(6):43-47.(in Chinese)马友龙,祁海艳,曹振东,等.多西紫杉醇纳米脂质体的制备及其对肝癌细胞的体内外治疗研究[J].中国生化药物杂志,2015,35(6):43-47.
|
[21]ZHANG T,DUAN RC,ZHANG R.A retrospective analysis of combination of gemcitabine and docetaxel in patients with advanced hepatocellular carcinoma[J].Cancer Res Prevent Treat,2102,39(11):1369-1372.(in Chinese)张彤,段仁慈,张蕊.吉西他滨联合多西紫杉醇方案治疗晚期肝癌的临床观察[J].肿瘤防治研究,2102,39(11):1369-1372.
|
1. | 朱宏坤,戴芳芳,钱世宁. 血必净注射液对行连续性肾脏替代疗法的多器官功能障碍综合征患者凝血功能的影响. 哈尔滨医科大学学报. 2024(01): 75-79 . ![]() | |
2. | 肖晶晶. 局部枸橼酸抗凝联合CRRT治疗脓毒症合并急性肾衰竭的临床疗效及对患者凝血功能的影响. 延边大学医学学报. 2024(05): 534-537 . ![]() | |
3. | 王娟,张丽萍,丁童,卫淑润,翁志华. 局部枸橼酸抗凝血液净化技术在ICU造血干细胞移植后弥漫性肺泡出血患者治疗中应用价值. 临床军医杂志. 2023(05): 522-524 . ![]() | |
4. | 孙卫和,许伟伟,冒秀宏,汪涛. 局部枸橼酸抗凝在重症急性肾损伤患者连续性肾脏替代治疗中的应用. 中外医疗. 2023(18): 129-132 . ![]() | |
5. | 赵志强,孟鹏飞,石正松,陈亚君,肖宏涛. 枸橼酸抗凝在脓毒症伴高危出血行连续性肾脏替代治疗患者中的应用效果. 医药论坛杂志. 2023(19): 14-18 . ![]() | |
6. | 李一青,白银果,沙莎. 连续性静脉-静脉血液滤过透析和局部枸橼酸抗凝在重症患者乳酸升高时应用的有效性和安全性研究. 贵州医药. 2023(11): 1704-1705 . ![]() | |
7. | 张妍,荣阳,张芳. CRRT治疗肾衰竭合并顽固性心力衰竭的临床效果. 中西医结合心脑血管病杂志. 2022(02): 285-288 . ![]() | |
8. | 张竞葳,田敏,余建斌. 局部枸橼酸抗凝应用于维持性血液透析合并消化道出血患者的疗效观察. 现代医学与健康研究电子杂志. 2022(13): 130-134 . ![]() | |
9. | 陈伟玲,邓虹,黄颖妍,李乐,张洪举. 局部枸橼酸抗凝在连续性肾替代疗法治疗中的效果及安全性指标的变化. 北方药学. 2022(05): 116-119 . ![]() | |
10. | 吴允东,江海娇,张伟,曹迎亚,杨尚志,周伟. 不同抗凝方案用于心脏术后患者连续性肾脏替代治疗中的效果. 皖南医学院学报. 2022(05): 436-439+443 . ![]() | |
11. | 严海燕,黄雪敏,李大亮,岑树坤,蒋林青. 局部枸橼酸抗凝在重症急性肾损伤患者连续性肾脏替代治疗中的应用分析. 实用中西医结合临床. 2022(17): 31-33+37 . ![]() | |
12. | 金源源,诸炳骅,费雪洁,王倩. 局部枸橼酸抗凝在肝衰竭患者连续性肾脏替代治疗中的应用. 临床肝胆病杂志. 2021(01): 200-203 . ![]() | |
13. | 胡新,毛智,周飞虎. 枸橼酸抗凝在重症患者连续血液净化中的应用进展. 武警医学. 2021(01): 78-81 . ![]() | |
14. | 杨向莎,杨福燕,张瑞霞,张军. 改良式枸橼酸钠与低分子量肝素在急性肾损伤CRRT中的抗凝效果比较. 临床医学研究与实践. 2021(20): 46-49 . ![]() | |
15. | 冉梦晓,陈辉,郑浩天. 枸橼酸局部抗凝技术在血液透析中的应用进展. 中国医药. 2021(07): 1113-1116 . ![]() | |
16. | 杨妮娜,李之诉,杨禄,陈王峰. RCA-CRRT治疗中滤器后离子钙与体内离子钙的相关性. 现代实用医学. 2021(08): 993-995 . ![]() | |
17. | 焦清海,郑丽环,张雪梅,王征,杜菲,陈亮. 局部枸橼酸抗凝在危重症患者持续肾脏替代疗法中的临床应用. 河北医科大学学报. 2021(10): 1144-1148 . ![]() | |
18. | 王敬文. 枸橼酸与肝素抗凝对重症血液净化患者临床指标和安全性的影响比较. 中外医学研究. 2021(32): 40-43 . ![]() | |
19. | 冯菁,李和文,张兴凯,王建华,张作鹏,郭燕蓉,任航奇. 肝衰竭患者行局部枸橼酸抗凝连续性肾脏替代治疗时发生枸橼酸蓄积的影响因素分析. 临床和实验医学杂志. 2021(22): 2402-2406 . ![]() | |
20. | 李杨,由丽丽. 连续性肾脏替代治疗脑出血合并急性肾损伤患者中应用局部枸橼酸抗凝治疗的有效性及安全性. 中国医药指南. 2020(36): 89-90 . ![]() |